Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F09%3A5814" target="_blank" >RIV/00064165:_____/09:5814 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/09:5814 RIV/00023736:_____/09:00008236

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery

Popis výsledku v původním jazyce

We report response to treatment of 5 pregnant women with CML during and after pregnancy. CML was diagnosed during pregnancy in 3 patients, while 2 patients became pregnant during CML. Interferon alpha with leukapheresis when needed was applied in the 2ndand 3rd trimester. We describe that all patients except one achieved complete hematological response during pregnancy. After delivery four patients achieved partial cytogenetic response on imatinib and two patients achieved major molecular response after crossover to dasatinib. We conclude that the pregnancy of our CML patients did not substantially negatively influence their further response to treatment, in comparison to other patients.

Název v anglickém jazyce

Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery

Popis výsledku anglicky

We report response to treatment of 5 pregnant women with CML during and after pregnancy. CML was diagnosed during pregnancy in 3 patients, while 2 patients became pregnant during CML. Interferon alpha with leukapheresis when needed was applied in the 2ndand 3rd trimester. We describe that all patients except one achieved complete hematological response during pregnancy. After delivery four patients achieved partial cytogenetic response on imatinib and two patients achieved major molecular response after crossover to dasatinib. We conclude that the pregnancy of our CML patients did not substantially negatively influence their further response to treatment, in comparison to other patients.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NR8758" target="_blank" >NR8758: Časné markery rezistence k imatinibu při léčbě chronické myeloidní leukemie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia Research

ISSN

0145-2126

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

3

Strana od-do

—

Kód UT WoS článku

000269870400024

EID výsledku v databázi Scopus

—